Meeshanthini Dogan
Directeur Général chez CARDIO DIAGNOSTICS HOLDINGS, INC.
Fortune : 1 M $ au 31/05/2024
Postes actifs de Meeshanthini Dogan
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| CARDIO DIAGNOSTICS HOLDINGS, INC. | Directeur/Membre du Conseil | 25/10/2022 | - |
| Directeur Général | 25/10/2022 | - | |
Cardio Diagnostics, Inc.
 Cardio Diagnostics, Inc. Medical/Nursing ServicesHealth Services Part of Cardio Diagnostics Holdings, Inc., Cardio Diagnostics, Inc. is a biotechnology company based in Chicago, IL. The company is focused on making cardiovascular disease prevention and early detection more accessible, personalized, and precise. The company's flagship solution, the Cardio Diagnostics Epi+Gen CHD™ test, helps clinicians better assess each patient's unique risk profile for disease. The company's vision is to transform medical care for cardiovascular disease from reactive to proactive. Cardio Diagnostics was founded in 2017 by Meeshanthini Dogan and Robert Philibert, with Meeshanthini Dogan serving as CEO since then. Cardio Diagnostics was acquired by Mana Capital Acquisition Corp. on October 25, 2022 for $61.51 million. | Directeur/Membre du Conseil | 01/05/2017 | - |
| Directeur Général | 01/05/2017 | - | |
| Fondateur | 01/05/2017 | - |
Historique de carrière de Meeshanthini Dogan
Formation de Meeshanthini Dogan
| University of Iowa | Doctorate Degree |
Statistiques
Internationale
| Etats-Unis | 4 |
Opérationnelle
| Director/Board Member | 2 |
| Chief Executive Officer | 2 |
| Founder | 1 |
Sectorielle
| Health Services | 2 |
| Health Technology | 2 |
| Consumer Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| CARDIO DIAGNOSTICS HOLDINGS, INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Cardio Diagnostics, Inc.
Cardio Diagnostics, Inc. Medical/Nursing ServicesHealth Services Part of Cardio Diagnostics Holdings, Inc., Cardio Diagnostics, Inc. is a biotechnology company based in Chicago, IL. The company is focused on making cardiovascular disease prevention and early detection more accessible, personalized, and precise. The company's flagship solution, the Cardio Diagnostics Epi+Gen CHD™ test, helps clinicians better assess each patient's unique risk profile for disease. The company's vision is to transform medical care for cardiovascular disease from reactive to proactive. Cardio Diagnostics was founded in 2017 by Meeshanthini Dogan and Robert Philibert, with Meeshanthini Dogan serving as CEO since then. Cardio Diagnostics was acquired by Mana Capital Acquisition Corp. on October 25, 2022 for $61.51 million. | Health Services |
- Bourse
- Insiders
- Meeshanthini Dogan
- Expérience
